Further funding is likely to be required because the Infusions business has not sold. Its revenues are down, so that might explain why. According to the 4C, negotiations for the sale continue. Also, there was an interesting comment about non-dilutive financing. The tenor of the 4C was positive. There was no hint of administration.
Class action, page-228
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.68 |
Change
-0.320(2.67%) |
Mkt cap ! $246.9M | |||
| Open | High | Low | Value | Volume |
| $11.57 | $11.81 | $11.42 | $152.5K | 13.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 116 | $11.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.68 | 188 | 1 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |